Fagron NV (ARSUF)
| Market Cap | 1.90B +8.1% |
| Revenue (ttm) | 1.18B +11.9% |
| Net Income | 104.81M +7.1% |
| EPS | 1.43 +6.8% |
| Shares Out | n/a |
| PE Ratio | 18.11 |
| Forward PE | 14.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,500 |
| Open | 27.50 |
| Previous Close | 27.50 |
| Day's Range | 27.00 - 27.50 |
| 52-Week Range | 23.50 - 27.90 |
| Beta | 0.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for av... [Read more]
Financial Performance
In 2025, Fagron NV's revenue was 952.17 million, an increase of 9.20% compared to the previous year's 871.96 million. Earnings were 91.02 million, an increase of 12.99%.
Financial numbers in EUR Financial StatementsNews
Fagron NV Earnings Call Transcript: H1 2026
H1 2026 saw 16% revenue growth to EUR 552.5 million, with strong organic and acquisition-driven gains in EMEA and Latin America offsetting North America Pacific headwinds. Adjusted EBITDA margin was 19.4%, and full-year guidance for mid to high single-digit growth and 20% margin is reiterated.
Fagron NV Earnings release: H1 2026
Fagron NV released its H1 2026 earnings on July 30, 2026, summarizing the period's financial results.
Fagron NV Slides: H1 2026
Fagron NV has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 30, 2026.
Fagron NV Quarterly report: H1 2026
Fagron NV has published its H1 2026 quarterly earnings report on July 30, 2026.
Fagron NV: Fagron shareholders approve all proposed resolutions at the General Meetings
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 May 2026 - 6PM CET Fagron shareholders approve all proposed resolutions at the General Meetings Fagron, the leading global p...
Fagron shareholders approve all proposed resolutions at the General Meetings
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 May 2026 – 6PM CET Fagron shareholders approve all proposed resolutions at the General Meetings Fagron, the leading global playe...
Pete Pharma and Fagron Enter Strategic Distribution Partnership to Expand Access to Pharmaceutical 3D Printing Across North America
PHOENIX--(BUSINESS WIRE)--Pete Pharma, a pharmaceutical innovation and IP development company focused on modernizing dosage forms through advanced 3D pharmaceutical printing, delivery systems, and sca...
Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2026 – 7 AM CEST Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026 Fagron NV invites its sharehold...
Fagron NV Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 10.3% to €263 million, driven by LatAm and M&A, with EBITDA margin guidance at 20%. Integration of recent acquisitions is on track, and the outlook remains positive with mid to high single-digit organic growth expected.
Fagron NV Earnings release: Q1 2026
Fagron NV released its Q1 2026 earnings on April 9, 2026, summarizing the period's financial results.
Fagron NV Slides: Q1 2026
Fagron NV has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 9, 2026.
Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the le...
Fagron increases share capital through exercise subscription rights
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of th...
Fagron NV Earnings Call Transcript: H2 2025
Revenue grew 9.2% to €952 million in 2025, with strong organic growth and margin expansion across all regions. Twelve acquisitions were announced, and integration is underway, while 2026 guidance calls for continued mid- to high single-digit growth and slight profitability improvement.
Fagron NV Earnings release: H2 2025
Fagron NV released its H2 2025 earnings on February 12, 2026, summarizing the period's financial results.
Fagron NV Slides: H2 2025
Fagron NV has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 12, 2026.
Fagron NV Annual report: H2 2025
Fagron NV has published its H2 2025 annual report on February 12, 2026.
Pharma 5.0 delivers personalized treatment using AI, says Fagron CEO
Rafael Padilla, CEO of pharmaceuticals company, Fagron, discusses healthcare innovation, obesity drug safety, and the company's growth strategy amid global pricing pressures.
Fagron Announces Acquisitions Of Amara And Magilab
(RTTNews) - Fagron (FAGR.BR) announced acquisitions of a book of business from Amara, and Magilab. Amara is a player in the compounding sector, operating raw materials in Poland. Magilab is a speciali...
Fagron NV Earnings Call Transcript: Q3 2025
Normalized organic growth reached 8.5% in Q3, with full-year revenue guidance reaffirmed at EUR 930–950 million and profitability set to improve. Eight acquisitions and major capacity expansions support global growth, while EMEA and North America delivered strong segment results.
Fagron NV Earnings release: Q3 2025
Fagron NV released its Q3 2025 earnings on October 9, 2025, summarizing the period's financial results.
Fagron NV Slides: Q3 2025
Fagron NV has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 9, 2025.
Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlook
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 October 2025 – 7:00 AM CET Fagron reports solid third quarter performance with 6.4% revenue growth and confi...
Fagron NV Earnings Call Transcript: H1 2025
H1 2025 saw 11.3% organic revenue growth, margin expansion to 20%, and strong performance across all regions, led by North America and LATAM. Four acquisitions expanded the global footprint, and guidance remains for mid to high single-digit organic growth and improved profitability.
Fagron NV Earnings release: H1 2025
Fagron NV released its H1 2025 earnings on July 31, 2025, summarizing the period's financial results.